89zr bevacizumab

From WikiMD's free health, diet & wellness encyclopedia
Jump to navigation Jump to search

89zr bevacizumab - a radioimmunoconjugate comprised of the recombinant humanized monoclonal antibody bevacizumab labeled with the radioisotope zirconium zr 89 (zr 89) with radioisotopic activity and potential imaging use. The antibody moiety of zirconium zr 89 bevacizumab targets and binds to the extracellular domain of the vascular endothelial growth factor receptor (vegfr). Upon binding, the radioisotope moiety may be detected using positron emission tomography (pet), allowing the imaging and quantification of vegfr expressing tumor cells. Vegfr, a tyrosine kinase, is overexpressed on the cell surfaces of various tumor cell types.

Up to date info


Latest research - 89zr bevacizumab

Clinical trials

Source: Data courtesy of the U.S. National Library of Medicine. Since the data might have changed, please query MeSH on 89zr bevacizumab for any updates.


89zr bevacizumab is part of WikiMD's free ^articles!

^89zr bevacizumab (article) is provided for informational purposes only. No expressed or implied warranties as to the validity of content.
WikiMD is not a substitute for professional advice. By accessing and using WikiMD you agree to the terms of use.
Templates etc. when imported from Wikipedia, are licensed under CC BY-SA 3.0. See full disclaimers.
W8MD weight loss logo

Ad. Tired of being overweight?. W8MD's physician weight loss program can HELP. Tele medicine available